Learn about our #GetNaked Campaign View Campaign
Guest blog post by Ian Michael Crumm, Celebrity Esthetician, Podcast Host, Key Opinion Leader, Melanoma Advocate and 2025 #GetNaked Spokesperson: Some moments stick with yo...
Guest blog post by Katie Doble, ocular melanoma (OM) survivor, MRF Courage Award recipient and OM advocate: TIL therapy has given my family and me next-level hope. At 31 ye...
The Melanoma Research Foundation (MRF) is pleased to share recent significant achievements for the melanoma community. In March 2022, the U.S. Food and Drug Administration ...
On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first geneti...
On February 25, 2022, the American Cancer Society Cancer Action Network (ACS-CAN) and the National Comprehensive Cancer Network (NCCN) sent a joint letter to the Majority a...
As the MRF observes Rare Disease Day on February 28, 2022, we celebrate the courageous and inspiring members of our community who are living with a rare melanoma subtype. M...
WASHINGTON, DC (February 23, 2022) – The Melanoma Research Foundation (MRF) will host nearly 100 advocates during the all-virtual MRF Advocacy Days held March 7-11, 2022....
Guest blog post by Monique Mack, “In the Sun” documentary participant, melanoma survivor and MRF advocate: My name is Monique Mack, and I am honored to be an advoca...
Guest blog post by Katonya Breaux, Founder, Unsun Cosmetics and MRF advocate: I discovered moles on my face that I thought were genetic, but after a visit to the dermato...
Guest blog post by Samantha Buirski, ocular melanoma patient, advocate and member of the CURE OM Patient Steering Committee: Being part of a rare community is challenging. ...
On January 26, 2022, the U.S. Food and Drug Administration announced the approval of KIMMTRAK (tebentafusp-tebn), the first and only FDA-approved treatment for metastatic u...
Guest blog post by Kristin R. McJunkins, Stage III melanoma survivor and advocate: In 2008 when I was 38 years old, I was diagnosed with Stage IIIa cutaneous melanoma. Afte...
Guest blog post by Keith T. Flaherty, MD, Associate Professor of Medicine at Harvard Medical School, Director of Developmental Therapeutics at Massachusetts General Hospita...
May 20, 2025
